Immunocore Holdings Plc Stock Price, News & Analysis

Immunocore Holdings (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines, has announced its participation in two upcoming investor conferences. The company will present at the Guggenheim Securities Healthcare Innovation Conference on Tuesday, November 12, 2024, at 1:00 p.m. EST, and the Jefferies London Healthcare Conference on Wednesday, November 21, 2024, at 9:00 a.m. GMT.

Both presentations will be available via webcast on Immunocore's website in the 'Events & Presentations' section, with replays available for a time after the events.

Immunocore (IMCR) reported strong Q3 2024 financial results with KIMMTRAK net revenues of $80.2 million, representing 28% growth over Q3 2023. The company achieved earnings per share of $0.17, compared to $0.02 in Q3 2023. KIMMTRAK is now approved in 38 countries and launched in 21 countries globally. The company continues to advance its pipeline with ongoing Phase 3 trials in cutaneous melanoma and plans to start randomization for the Phase 3 ATOM trial in adjuvant uveal melanoma in Q4 2024. Cash position remains strong at $901.3 million as of September 30, 2024.

Immunocore Holdings plc (Nasdaq: IMCR) presented Phase 1 data for brenetafusp, an ImmTAC bispecific targeting PRAME, in platinum-resistant ovarian cancer patients at the 2024 ESMO Congress. Key findings include:

1. Monotherapy: 58% disease control rate, 6.5% RECIST response rate, and 3.3 months median PFS in heavily pre-treated patients.

2. Chemotherapy combination: 69% disease control rate and 23% RECIST response rate.

3. T cell fitness (TCF) gene expression signature in blood associated with improved clinical outcomes across different tumor types.

The data suggests potential for brenetafusp in ovarian cancer, particularly in earlier-line treatment where TCF is expected to be higher.

Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company, which focuses on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, will be part of a fireside chat on Thursday, September 19, 2024, at 12:45 p.m. EDT.

The presentation will be webcast live and can be accessed through the 'Events & Presentations' section under 'Events' on the 'Investors' page of Immunocore's website. A replay of the presentation will be available for a time after the event.

Immunocore Holdings plc (Nasdaq: IMCR) announced that its Chief Financial Officer (CFO) and Head of Strategy, Brian Di Donato, will be leaving the company at the end of 2024. Di Donato has accepted a position as CEO of a private, early-stage biotech in San Diego. He will remain in his current role through the end of the year to ensure a smooth transition, while Immunocore initiates a search for a new CFO.

CEO Bahija Jallal praised Di Donato's contributions over his four-year tenure, highlighting his role in the company's successful IPO and building a strong Finance department. Di Donato expressed pride in Immunocore's achievements, including becoming a commercial-stage biotech with the launch of the world's first TCR therapy.

Immunocore Holdings plc (Nasdaq: IMCR) reported Q2 2024 financial results and provided a business update. Key highlights include:

- KIMMTRAK net revenues of $75.3 million in Q2 2024, driven by US growth

- Ongoing Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma

- Started randomization for Phase 3 PRISM-MEL-301 trial evaluating brenetafusp + nivolumab in first-line cutaneous melanoma

- Presented Phase 1 data of brenetafusp in late-line cutaneous melanoma at ASCO 2024

- R&D expenses increased to $51.1 million in Q2 2024

- Cash, cash equivalents, and marketable securities at $859.6 million as of June 30, 2024

The company is advancing multiple clinical programs and expects data readouts over the next 18 months.

Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company, has announced it will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the US markets open. The company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss the financial results and provide a business and portfolio update.

Investors and interested parties can access the audio webcast through the 'Events' section under 'Events and Presentations' on Immunocore's website. For those who prefer to join via phone, domestic toll-free and international toll numbers have been provided. A replay of the event will be available for a time after the call.

Immunocore announced the randomization of the first patient in its global Phase 3 PRISM-MEL-301 trial. This trial assesses the efficacy and safety of brenetafusp (IMC-F106C; PRAME-A02) combined with nivolumab, compared to nivolumab or nivolumab + relatlimab in treating first-line advanced or metastatic cutaneous melanoma. The trial targets HLA-A*02:01 positive patients. Brenetafusp is a PRAME x CD3 ImmTAC bispecific protein. Previous Phase 1 data showed it was well tolerated and demonstrated promising monotherapy activity.

Immunocore presented new clinical data for KIMMTRAK at the 2024 ASCO Annual Meeting. The data showed that patients with unresectable or metastatic uveal melanoma who had stable disease and confirmed tumor reduction experienced similar clinical outcomes to those with a partial response. The Phase 2 trial indicated that 25% of 127 patients had any tumor reduction, including 6 partial responses. In the Phase 3 trial, the durability of tumor reduction was similar for patients with stable disease and partial response, both lasting 11 months. This reinforces KIMMTRAK as a standard treatment for HLA-A*02:01-positive patients.